Article PDF
References
Vale W, Spiess J, Rivier C, Rivier J, 1981 Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394–1397.
Chrousos GP, 1995 The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351–1362.
Owens MJ, Nemeroff CB, 1991 Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43: 425–473.
Gold PW, Chrousos GP, 2002 Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 7: 254–275.
Keck ME, Holsboer F, 2001 Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 22: 835–844.
Reul JM, Holsboer F, 2002 Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2: 23–33.
Dautzenberg FM, Kilpatrick GJ, Hauger RL, Moreau J, 2001 Molecular biology of the CRH receptors- in the mood. Peptides 22: 753–760.
Behan DP, Heinrichs SC, Troncoso JC, et al, 1995 Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer’s disease. Nature 378: 284–287.
De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW, 1986 Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer’s disease. Nature 319: 593–595.
Makrigiannakis A, Zoumakis E, Kalantaridou S, et al, 2001 Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol 2: 1018–1024.
Chrousos GP, Torpy DJ, Gold PW, 1998 Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 129: 229–240.
Martinez V, Rivier J, Wang L, Tache Y, 1997 Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J Pharmacol Exp Ther 280: 754–760.
Orth DN, 1992 Corticotropin-releasing hormone in humans. Endocr Rev 13: 164–191.
Parkes DG, Weisinger RS, May CN, 2001 Cardiovascular actions of CRH and urocortin: an update. Peptides 22: 821–827.
Venihaki M, Dikkes P, Carrigan A, Karalis KP, 2001 Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 108: 1159–1166.
Venihaki M, Majzoub JA, 1999 Animal models of CRH deficiency. Front Neuroendocrinol 20: 122–145.
Zoumakis E, Margioris AN, Makrigiannakis A, Stournaras C, Gravanis A, 1997 Human endometrium as a neuroendocrine tissue: expression, regulation and biological roles of endometrial corticotropin-releasing hormone (CRH) and opioid peptides. J Endocrinol Invest 20: 158–167.
Wang L, Martinez V, Rivier JE, Tache Y, 2001 Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2. Am J Physiol Regul Integr Comp Physiol 281: R1401–1410.
Martinez V, Wang L, Rivier JE, Vale W, Tache Y, 2002 Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 301: 611–617.
Coste SC, Kesterson RA, Heldwein KA, et al, 2000 Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24: 403–409.
Coste SC, Quintos RF, Stenzel-Poore MP, 2002 Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress. Trends Cardiovasc Med 12: 176–182.
Karalis K, Sano H, Redwine J, et al, 1991 Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254: 421–423.
Agelaki S, Tsatsanis C, Gravanis A, Margioris AN, 2002 Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 70: 6068–6074.
Chatzaki E, Charalampopoulos I, Leontidis C, et al, 2003 Urocortin in human gastric mucosa: relationship to inflammatory activity. J Clin Endocrinol Metab 88: 478–483.
Koob GF, Bloom FE, 1985 Corticotropin-releasing factor and behavior. Fed Proc 44: 259–263.
Kempuraj D, Papadopoulou NG, Lytinas M, et al, 2004 Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145: 43–48.
Rivier J, Spiess J, Vale W, 1983 Characterization of rat hypothalamic corticotropin-releasing factor. Proc Natl Acad Sci U S A 80: 4851–4855.
Shibahara S, Morimoto Y, Furutani Y, et al, 1983 Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. Embo J 2: 775–779.
Ling N, Esch F, Bohlen P, Baird A, Guillemin R, 1984 Isolation and characterization of caprine corticotropin-releasing factor. Biochem Biophys Res Commun 122: 1218–1224.
Esch F, Ling N, Bohlen P, et al, 1984 Isolation and char-acterization of the bovine hypothalamic corticotropin-releasing factor. Biochem Biophys Res Commun 122: 899–905.
Patthy M, Horvath J, Mason-Garcia M, et al, 1985 Isolation and amino acid sequence of corticotropin-releasing factor from pig hypothalami. Proc Natl Acad Sci U S A 82: 8762–8766.
Okawara Y, Morley SD, Burzio LO, et al, 1988 Cloning and sequence analysis of cDNA for corticotropin-releasing factor precursor from the teleost fish Catostomus commersoni. Proc Natl Acad Sci U S A 85: 8439–8443.
Stenzel-Poore MP, Heldwein KA, Stenzel P, Lee S, Vale WW, 1992 Characterization of the genomic corticotropin-releasing factor (CRF) gene from Xenopus laevis: two members of the CRF family exist in amphibians. Mol Endocrinol 6: 1716–1724.
Montecucchi PC, Henschen A, 1981 Amino acid composition and sequence analysis of sauvagine, a new active peptide from the skin of Phyllomedusa sauvagei. Int J Pept Protein Res 18: 113–120.
Lederis K, Letter A, McMaster D, Moore G, Schlesinger D, 1982 Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Science 218: 162–165.
Reyes TM, Lewis K, Perrin MH, et al, 2001 Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98: 2843–2848.
Lewis K, Li C, Perrin MH, et al, 2001 Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 98: 7570–7575.
Pallai PV, Mabilia M, Goodman M, Vale W, Rivier J, 1983 Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: circular dichroism and prediction studies. Proc Natl Acad Sci U S A 80: 6770–6774.
Dathe M, Fabian H, Gast K, et al, 1996 Conformational differences of ovine and human corticotropin releasing hormone. A CD, IR, NMR and dynamic light scattering study. Int J Pept Protein Res 47: 383–393.
Lau SH, Rivier J, Vale W, Kaiser ET, Kezdy FJ, 1983 Surface properties of an amphiphilic peptide hormone and of its analog: corticotropin-releasing factor and sauvagine. Proc Natl Acad Sci U S A 80: 7070–7074.
Rivier J, Rivier C, Vale W, 1984 Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 224: 889–891.
Beyermann M, Rothemund S, Heinrich N, et al, 2000 A role for a helical connector between two receptor binding sites of a long-chain peptide hormone. J Biol Chem 275: 5702–5709.
O’Neil KT, DeGrado WF, 1990 A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 250: 646–651.
Ohta N, Mochizuki T, Hoshino M, et al, 1997 Adreno-corticotropic hormone-releasing activity of urotensin I and its fragments in vitro. J Pept Res 50: 178–183.
Kornreich WD, Galyean R, Hernandez JF, et al, 1992 Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship study. J Med Chem 35: 1870–1876.
Gulyas J, Rivier C, Perrin M, et al, 1995 Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A 92: 10575–10579.
Chen R, Lewis KA, Perrin MH, Vale WW, 1993 Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 90: 8967–8971.
Harmar AJ, 2001 Family-B G-protein-coupled receptors. Genome Biol 2: REVIEWS3013.
Arai M, Assil IQ, Abou-Samra AB, 2001 Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis. Endocrinology 142: 446–454.
Hillhouse EW, Grammatopoulos DK, 2006 The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27: 260–286.
Ardati A, Goetschy V, Gottowick J, et al, 1999 Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. Neuropharmacology 38: 441–448.
Kostich WA, Chen A, Sperle K, Largent BL, 1998 Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 12: 1077–1085.
Rivier J, Gulyas J, Kirby D, et al, 2002 Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45: 4737–4747.
Rivier J, Gulyas J, Kunitake K, et al, 2007 Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. J Med Chem 50: 1668–1674.
Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J, 1998 Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A 95: 15264–15269.
Lawrence AJ, Krstew EV, Dautzenberg FM, Ruhmann A, 2002 The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br J Pharmacol 136: 896–904.
Tezval H, Jahn O, Todorovic C, et al, 2004 Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc Natl Acad Sci U S A 101: 9468–9473.
Graziani G, Tentori L, Portarena I, et al, 2002 CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143: 807–813.
Haug T, Storm JF, 2000 Protein kinase A mediates the modulation of the slow Ca(2+)-dependent K(+) current, I(sAHP), by the neuropeptides CRF, VIP, and CGRP in hippocampal pyramidal neurons. J Neurophysiol 83: 2071–2079.
Papadopoulou N, Chen J, Randeva HS, et al, 2004 Protein kinase A-induced negative regulation of the corticotropin-releasing hormone R1alpha receptor-extracellularly regulated kinase signal transduction pathway: the critical role of Ser301 for signaling switch and selectivity. Mol Endocrinol 18: 624–639.
Sheng H, Sun T, Cong B, et al, 2008 Corticotropin-releasing hormone stimulates SGK-1 kinase expression in cultured hippocampal neurons via CRH-R1. Am J Physiol Endocrinol Metab 295: E938–946.
Kovalovsky D, Refojo D, Liberman AC, et al, 2002 Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 16: 1638–1651.
Brar BK, Chen A, Perrin MH, Vale W, 2004 Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 145: 1718–1729.
Traver S, Marien M, Martin E, Hirsch EC, Michel PP, 2006 The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol 70: 30–40.
Melzig MF, Papsdorf G, Loose R, et al, 1998 Effects of long term treatment with corticotropin releasing factor on corticotropic tumor cells in vitro. Regul Pept 74: 35–40.
Dautzenberg FM, Gutknecht E, Van der Linden I, et al, 2004 Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochem Pharmacol 68: 1833–1844.
Punn A, Levine MA, Grammatopoulos DK, 2006 Identification of signaling molecules mediating corticotropin-releasing hormone-R1alpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol Endocrinol 20: 3179–3195.
Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW, 2000 Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinol 14: 2076–2091.
Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN, 2002 Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase. J Biol Chem 277: 12280–12287.
Markovic D, Punn A, Lehnert H, Grammatopoulos DK, 2008 Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 22: 689–706.
Refojo D, Echenique C, Muller MB, et al, 2005 Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc Natl Acad Sci U S A 102: 6183–6188.
Karteris E, Hillhouse EW, Grammatopoulos D, 2004 Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility. Endocrinology 145: 890–900.
Chang CP, Pearse RV 2nd, O’Connell S, Rosenfeld MG, 1993 Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11: 1187–1195.
Kishimoto T, Pearse RV, 2nd, Lin CR, Rosenfeld MG, 1995 A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A 92: 1108–1112.
Lovenberg TW, Liaw CW, Grigoriadis DE, et al, 1995 Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 92: 836–840.
Perrin M, Donaldson C, Chen R, et al, 1995 Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 92: 2969–2973.
Nabhan C, Xiong Y, Xie LY, Abou-Samra AB, 1995 The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-1 cells, is not well coupled to the G protein(s). Biochem Biophys Res Commun 212: 1015–1021.
Markovic D, Papadopoulou N, Teli T, et al, 2006 Differential responses of corticotropin-releasing hormone receptor type 1 variants to protein kinase C phosphorylation. J Pharmacol Exp Ther 319: 1032–1042.
Markovic D, Grammatopoulos DK, 2010 Characterization of structural determinants of type 1 corticotropin releasing hormone (CRH) receptor signalling properties. Methods Mol Biol 634: 285–307.
Grammatopoulos DK, Dai Y, Randeva HS, et al, 1999 A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh trans-membrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol 13: 2189–2202.
Myers DA, Trinh JV, Myers TR, 1998 Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant. Mol Cell Endocrinol 144: 21–35.
Punn A, Chen J, Delidaki M, et al, 2012 Mapping structural determinants within 3rd intracellular loop that direct signalling specificity of type 1 corticotropin releasing hormone receptor. J Biol Chem 287: 8974–8985.
Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW, 1998 The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology 139: 566–570.
Perrin MH, Fischer WH, Kunitake KS, et al, 2001 Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. J Biol Chem 276: 31528–31534.
Perrin MH, DiGruccio MR, Koerber SC, et al, 2003 A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity. J Biol Chem 278: 15595–15600.
Klose J, Fechner K, Beyermann M, et al, 2005 Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions. Biochemistry 44: 1614–1623.
Dautzenberg FM, Wille S, Lohmann R, Spiess J, 1998 Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proc Natl Acad Sci USA 95: 4941–4946.
Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM, 1999 Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high-affinity ligand binding. J Neurochem 72: 388–395.
Pioszak AA, Parker NR, Suino-Powell K, Xu HE, 2008 Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. J Biol Chem 283: 32900–32912.
Grace CR, Perrin MH, Gulyas J, et al, 2007 Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci U S A 104: 4858–4863.
Hofmann BA, Sydow S, Jahn O, et al, 2001 Functional and protein chemical characterization of the N-terminal domain of the rat corticotropin-releasing factor receptor 1. Protein Sci 10: 2050–2062.
Qi LJ, Leung AT, Xiong Y, Marx KA, Abou-Samra AB, 1997 Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry 36: 12442–12448.
Grace CR, Perrin MH, DiGruccio MR, et al, 2004 NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci U S A 101: 12836–12841.
Assil-Kishawi I, Abou-Samra AB, 2002 Sauvagine cross-links to the second extracellular loop of the corticotropin-releasing factor type 1 receptor. J Biol Chem 277: 32558–32561.
Assil-Kishawi I, Samra TA, Mierke DF, Abou-Samra AB, 2008 Residue 17 of sauvagine cross-links to the first transmembrane domain of corticotropin-releasing factor receptor 1 (CRFR1). J Biol Chem 283: 35644–35651.
Gkountelias K, Tselios T, Venihaki M, et al, 2009 Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Mol Pharmacol 75: 793–800.
Kraetke O, Holeran B, Berger H, et al, 2005 Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues. Biochemistry 44: 15569–15577.
Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA, 1997 Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11: 2048–2053.
Liaw CW, Grigoriadis DE, Lovenberg TW, De Souza EB, Maki RA, 1997 Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol Endocrinol 11: 980–985.
Sydow S, Flaccus A, Fischer A, Spiess J, 1999 The role of the fourth extracellular domain of the rat corticotro-pin-releasing factor receptor type 1 in ligand binding. Eur J Biochem 259: 55–62.
Hoare SR, Fleck BA, Gross RS, et al, 2008 Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation. Mol Pharmacol 73: 1371–1380.
Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH, Vale WW, 2000 Constitutive activation of tethered-peptide/ corticotropin-releasing factor receptor chimeras. Proc Natl Acad Sci U S A 97: 10277–10281.
Hoare SR, Brown BT, Santos MA, et al, 2006 Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor. Biochem Pharmacol 72: 244–255.
Liapakis G, Ballesteros JA, Papachristou S, et al, 2000 The forgotten serin. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J Biol Chem 275: 37779–37788.
Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA, 1994 Structure and function of G protein-coupled receptors. Annu Rev Biochem 63: 101–132.
Lu ZL, Hulme EC, 1999 The functional topography of transmembrane domain 3 of the M1 muscarinic acetyl-choline receptor, revealed by scanning mutagenesis. J Biol Chem 274: 7309–7315.
Wess J, Maggio R, Palmer JR, Vogel Z, 1992 Role of conserved threonine and tyrosine residues in acetyl-choline binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J Biol Chem 267: 19313–19319.
Donnelly D, 1997 The arrangement of the transmembrane helices in the secretin receptor family of G-protein-coupled receptors. FEBS Lett 409: 431–436.
Frimurer TM, Bywater RP, 1999 Structure of the integral membrane domain of the GLP1 receptor. Proteins 35: 375–386.
Gether U, 2000 Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21: 90–113.
Gkountelias K, Papadokostaki M, Javitch JA, Liapakis G, 2010 Exploring the binding site crevice of a family B G protein-coupled receptor, the type 1 corticotropin releasing factor receptor. Mol Pharmacol 78: 785–793.
Gkountelias K, Spyridaki K, Giannopoylos P, et al, 2011 Determination of Residues in the Third Membrane-Spanning Segment of CRF1, which are Accessible in the Ligand Binding-Site Crevice of Receptor. The 29th Cyprus-Camerino-Noordwijkerhout Trends in Drug Research Medicinal Chemistry EFMC Symposium, Limassol, Cyprus.
Nova Pharmaceutical Corporation, 1990 Corticotropin-releasing factor antagonism compounds. US Patent Office.
Beck JP, Curry MA, Chorvat RJ, et al, 1999 Thiazolo[4,5-d]pyrimidine thiones and -ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists. Bioorg Med Chem Lett 9: 1185–1188.
Huang CQ, Wilcoxen K, McCarthy JR, et al, 2003 Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists. Bioorg Med Chem Lett 13: 3375–3379.
Yoon T, De Lombaert S, Brodbeck R, et al, 2008 The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists. Bioorg Med Chem Lett 18: 891–896.
Yoon T, De Lombaert S, Brodbeck R, et al, 2008 2-Arylpyrimidines: novel CRF-1 receptor antagonists. Bioorg Med Chem Lett 18: 4486–4490.
Arvanitis AG, Gilligan PJ, Chorvat RJ, et al, 1999 Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J Med Chem 42: 805–818.
Whitten JP, Xie YF, Erickson PE, et al, 1996 Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists. J Med Chem 39: 4354–4357.
Chen C, Dagnino R, Jr, De Souza EB, et al, 1996 Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med.Chem. 39: 4358–4360.
Chen YL, Obach RS, Braselton J, et al, 2008 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotro-pin-releasing factor 1 antagonists. J Med Chem 51: 1385–1392.
Wustrow DJ, Capiris T, Rubin R, et al, 1998 Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg Med Chem Lett 8: 2067–2070.
Chen C, Grigoriadis D 2005 NBI 30775 (R121919), an orally active antagonist of the corticotropin-releasing factor (CRF) type-1 receptor for the treatment of anxiety and depression. In: Drug Dev. Res. (eds), Wiley Subscription Services Inc., A Wiley Company; pp, 216–226.
Holsboer F, Ising M, 2008 Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350–357.
Tellew JE, Lanier M, Moorjani M, et al, 2010 Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett 20: 7259–7264.
Beck JP, Arvanitis AG, Curry MA, et al, 1999 Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists. Bioorg Med Chem Lett 9: 967–972.
Webster EL, Lewis DB, Torpy DJ, et al, 1996 In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137: 5747–5750.
Deak T, Nguyen KT, Ehrlich AL, et al, 1999 The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140: 79–86.
Nielsen DM, Carey GJ, Gold LH, 2004 Antidepressant-like activity of corticotropin- releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499: 135–146.
Habib KE, Weld KP, Rice KC, et al, 2000 Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97: 6079–6084.
McCarthy JR, Heinrichs SC, Grigoriadis DE, 1999 Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 5: 289–315.
Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A, 2002 Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188–199.
Briscoe RJ, Cabrera CL, Baird TJ, Rice KC, Woods JH, 2000 Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats. Brain Res 881: 204–207.
Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF, 2007 Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61: 78–86.
Chu K, Koob GF, Cole M, Zorrilla EP, Roberts AJ, 2007 Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav 86: 813–821.
Marinelli PW, Funk D, Juzytsch W, et al, 2007 The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychop-harmacology (Berl) 195: 345–355.
Stinus L, Cador M, Zorrilla EP, Koob GF, 2005 Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30: 90–98.
Webster E, Barrientos R, Contoreggi C, 2002 Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol 29: 1252–1261.
Gabry K, Chrousos G, Rice K, 2002 Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Mol Psychiatry 7): 474–483.
Greenwood-Van Meerveld B, Johnson A, Cochrane S, 2005 Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterol Motil 17: 415–422.
Martinez V, Taché Y, 2006 CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 12: 4071–4088.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fahmy, H., Spyridaki, K., Kuppast, B. et al. The “homeostasis hormone” and its CRF1 receptor. From structure to function. Hormones 11, 254–271 (2012). https://doi.org/10.14310/horm.2002.1355
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1355